TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Dosing Completed on Human Clinical Nicotine Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has completed dosing for 36 subjects in its human clinical oral nicotine study: NIC-H22-1. According to the announcement, the study is the result of the focus Lexaria has had for years on oral nicotine formulations as an alternative to vaping or smoking; the company noted that results from the study could lead to more rapid commercial adoption and distribution of its patented DehydraTECH(TM) absorption technology, which is designed to improve oral uptake. Statistics show that some 7 million people die every year from cigarette smoking, and alternatives for nicotine delivery…